Featured Research

from universities, journals, and other organizations

Protein Found To Identify Malignant Melanoma

Date:
July 20, 2008
Source:
University of Rochester Medical Center
Summary:
Researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women. The protein, IMP-3, is not over-expressed in harmless moles but is increased in the most dangerous types of skin cancer, and in a subset of lesions that can be difficult to predict called thin melanomas.

University of Rochester Medical Center researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women.

Related Articles


The protein, IMP-3, is not over-expressed in harmless moles but is increased in the most dangerous types of skin cancer, and in a subset of lesions that can be difficult to predict called thin melanomas. The finding offers a potential target for treatment -- but perhaps most importantly might give doctors a new, objective way to distinguish melanoma from some benign moles that look like melanoma but are not cancerous.

"We are very excited about our finding that IMP-3 is an important progression marker in malignant melanoma," said first author Jennifer G. Pryor, M.D., a third-year resident in the URMC Department of Pathology and Laboratory Medicine. "Although we have learned a lot about melanoma in recent years, it has unique biologic properties that sometimes make it difficult to diagnose and to plan for the proper treatment. This protein may have a key role in helping us to understand and distinguish between various types of melanocytic lesions."

This summer the National Cancer Institute warned that new cases of melanoma among young women jumped 50 percent since 1980. Possible explanations, medical experts said, include increased use of tanning beds and more time spent outdoors. Overall rates of melanoma have also been rising among older adults.

The pilot study investigated samples of 56 biopsied lesions from 48 adults. The lesions fell into the category of cutaneous melanocytic neoplasms, a diverse group that includes benign moles; Spitz nevi, a type of mole seen in younger people that can be easily mistaken for melanoma but is not cancerous; and malignant melanoma, which has several phases of growth.

Pathologists play a major role in diagnosing and staging skin cancers, by sorting through neoplasms and identifying features. They analyze cells within the lesions and apply chemical stains and other tools to measure the depth and predict future behavior of the growths.

This study by Pryor and co-authors showed why IMP-3 might be an important tool for pathologists. None of the benign moles or the benign moles with irregular features and some abnormal cells over-expressed the IMP-3 protein. However, the protein was produced excessively in most melanomas, and overly expressed more often in metastatic melanomas.

IMP-3 was also over-expressed in rare cases of invasive thin melanomas. This is significant because most thin melanomas have a good prognosis, but some act more aggressively and currently there is no accurate way to distinguish between the types of thin lesions.

IMP-3 is an insulin-like growth factor-II mRNA binding protein. It is involved in cell proliferation and appears to play a role in tumor formation in a number of cancers.

In previous studies expression of the IMP-3 protein has been linked to pancreas, kidney, ovary and lung cancers, but this is the first published study to demonstrate a connection to melanoma, Pryor said.

Additional research is needed to compare IMP-3 expression with long-term survival data from thin melanoma patients, to find out if patients whose tumors express IMP-3 might benefit from more careful monitoring and aggressive treatment, the study noted.

The antibody used in this research was obtained from the Dako Corporation of California, through a collaborative arrangement initiated by the corresponding author, Haodong Xu, M.D., Ph.D., associate professor of Pathology and Laboratory Medicine at URMC. Xu and his colleagues have previously published studies of IMP-3 as a potential therapeutic target for high grade neuroendocrine carcinomas.

The URMC Department of Pathology and Laboratory Medicine funded the research. Additional co-authors on the paper include Patricia A Bourne, former laboratory supervisor; Qi Yang, laboratory technologist; Glynis Scott, M.D., professor, URMC Department of Dermatology; and Betsy O. Spaulding, of the Dako Corporation.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Pryor et al. IMP-3 is a novel progression marker in malignant melanoma. Modern Pathology, 2008; 21 (4): 431 DOI: 10.1038/modpathol.3801016

Cite This Page:

University of Rochester Medical Center. "Protein Found To Identify Malignant Melanoma." ScienceDaily. ScienceDaily, 20 July 2008. <www.sciencedaily.com/releases/2008/07/080717110231.htm>.
University of Rochester Medical Center. (2008, July 20). Protein Found To Identify Malignant Melanoma. ScienceDaily. Retrieved March 27, 2015 from www.sciencedaily.com/releases/2008/07/080717110231.htm
University of Rochester Medical Center. "Protein Found To Identify Malignant Melanoma." ScienceDaily. www.sciencedaily.com/releases/2008/07/080717110231.htm (accessed March 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
What's Different About This Latest Ebola Vaccine

What's Different About This Latest Ebola Vaccine

Newsy (Mar. 26, 2015) — A whole virus Ebola vaccine has been shown to protect monkeys exposed to the virus. Here&apos;s what&apos;s different about this vaccine. Video provided by Newsy
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) — Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins